Evidence map›Paper›PMID 25093884›Full record

ArticleNature biotechnology2014

The global intellectual property landscape of induced pluripotent stem cell technologies.

MacKenna Roberts, Ivan B Wall, Ian Bingham, Dominic Icely, Brock Reeve, Kim Bure, Anna French, David A Brindley

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Human brain organoid code of conduct.Frontiers in molecular medicine · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

MacKenna RobertsOxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.
Ivan B Wall1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] Department of Biochemical Engineering, University College London, London, UK. [3] Department of Nanobiomedical Science and BK21 Plus NBM, Global Research Center of Regenerative Medicine, Dankook University, Cheonan, Republic of Korea. [4] Biomaterials and Tissue Engineering Lab, Department of Nanobiomedical Science and World Class University Research Center, Dankook University, Cheonan, Republic of Korea.
Ian BinghamIP Asset LLP, Oxford, UK.
Dominic IcelyIP Asset LLP, Oxford, UK.
Brock ReeveThe Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
Kim BureSartorius Stedim, Göttingen, Germany.
Anna French1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2].
David A Brindley1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] The Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. [3] Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK. [4] Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK. [5].

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Induced Pluripotent Stem CellsIntellectual PropertyInternationalityBiotechnologyPatents as Topic

Identifiers

PMID25093884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.